ArticleBMJ open2016

Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.

Michael McFarlane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.